The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Condition: Nonalcoholic Fatty Liver Disease Interventions: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Drug: Placebo - Study Part One; Drug: Placebo - Study Part Two Sponsor: ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
EUS-guided Versus Percutaneous Ultrasound-guided Biopsy for Parenchymal Liver Disease
Condition: Liver Cirrhosis Interventions: Diagnostic Test: EUS guided liver biopsy; Diagnostic Test: Percutaneous Liver Biopsy Sponsor: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Condition: Nonalcoholic Fatty Liver Disease Interventions: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Drug: Placebo - Study Part One; Drug: Placebo - Study Part Two Sponsor: ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
EUS-guided Versus Percutaneous Ultrasound-guided Biopsy for Parenchymal Liver Disease
Condition: Liver Cirrhosis Interventions: Diagnostic Test: EUS guided liver biopsy; Diagnostic Test: Percutaneous Liver Biopsy Sponsor: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Condition: Nonalcoholic Fatty Liver Disease Interventions: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Drug: Placebo - Study Part One; Drug: Placebo - Study Part Two Sponsor: ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Conditions: Nonalcoholic Fatty Liver Disease Interventions: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Drug: Placebo - Study Part One; Drug: Placebo - Study Part Two Sponsors: ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Prediction of Early Recovery of Liver Function After LDLT in Children: An Ambispective Cohort Study
Conditions: Liver and Biliary Tract Disorders in Duration of Pregnancy; Other End-stage Liver Diseases in Children Sponsors: Huiwu Xing Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
Conditions: Type 2 Diabetes; Non Alcholic Fatty Liver Disease Intervention: Drug: Bempedoic acid Sponsors: Medanta, The Medicity, India; Diabetes & Endocrinology Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Randomized Controlled Trial
Conditions: Type 2 Diabetes; Non Alcholic Fatty Liver Disease Intervention: Drug: Bempedoic acid Sponsors: Medanta, The Medicity, India; Diabetes & Endocrinology Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
